To read the full article sign up for free or sign in.

Tracon quits work on anti-PD-L1 envafolimab after phase III flop

July 2, 2024

Tracon Pharmaceuticals Inc. is shuttering all development of its subcutaneous PD-L1 antibody, envafolimab, after the pivotal trial failed to meet the primary endpoint in soft tissue sarcoma.

BioWorld BioWorld Asia Clinical Regulatory Cancer Antibody Asia-Pacific China U.S. NMPA

Today's news in brief

BioWorld

BioWorld briefs for Aug. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 29, 2025.

Letting lab mice run wild improves preclinical translatability

BioWorld

“The impoverished laboratory environment in which mice and rats are maintained has been very good at increasing experimental replicability,” Steven Austad told...

Sideroflexin 1 is potential therapeutic target in bladder cancer

BioWorld Science

Bladder cancer is among the 10 most frequent cancers around the world. While potentially effective treatments exist, they do not benefit all patients, so...

Serum α-1-microglobulin is biomarker in aortic valve stenosis

BioWorld Science

Calcific aortic valve disease (CAVD) is the most prevalent acquired valve heart disorder in aging populations. Its most severe form in aortic valve stenosis...